Literature DB >> 36187516

Impact of Morbid Obesity on the Outcomes of Type II Endometrial Cancer: a Cohort Study.

Khaled Gaballa1, Islam H Metwally1, Basel Refky1, Shadi Awny1, Mohamed Abdelkhalek1, Mohamed Hamdy1.   

Abstract

Obesity has long been associated with endometrial cancer. However, there is a paucity of studies addressing the impact of morbid obesity in type II endometrial cancer on oncologic and surgical outcomes. In this study, the author retrospectively compared morbid to non-morbid obese in clinico-epidemiologic, surgical, and oncologic outcomes. Both groups were comparable as regards all clinico-epidemiologic parameters. Vaginal involvement, survival, and recurrence were also comparable between the 2 groups. Para-aortic adenopathy and treatment with preoperative therapy were the only significant predictors of DFS. Surgery is feasible with equivalent complications and oncologic outcomes in morbidly obese patients with type II endometrial cancer. © Indian Association of Surgical Oncology 2022.

Entities:  

Keywords:  Endometrial cancer; Hysterectomy; Obesity Non-endometrioid carcinoma

Year:  2022        PMID: 36187516      PMCID: PMC9515259          DOI: 10.1007/s13193-022-01503-z

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  30 in total

1.  Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.

Authors:  Hidemichi Watari; Yukiharu Todo; Mahito Takeda; Yasuhiko Ebina; Ritsu Yamamoto; Noriaki Sakuragi
Journal:  Gynecol Oncol       Date:  2005-03       Impact factor: 5.482

2.  Body size in relation to cancer of the uterine corpus in 1 million Norwegian women.

Authors:  Tone Bjørge; Anders Engeland; Steinar Tretli; Elisabete Weiderpass
Journal:  Int J Cancer       Date:  2007-01-15       Impact factor: 7.396

3.  Obesity as a risk factor of in-hospital outcomes in patients with endometrial cancer treated with traditional surgical mode.

Authors:  Slawomir M Januszek; Edyta Barnas; Joanna Skret-Magierlo; Jakub Sokolowski; Pawel Sczerba; Rafal Januszek; Wojciech Domka; Tomasz Lozinski; Marek Kluza; Tomasz Kluz
Journal:  Ginekol Pol       Date:  2019       Impact factor: 1.232

4.  Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium.

Authors:  J R Lurain; B L Rice; A W Rademaker; L E Poggensee; J C Schink; D S Miller
Journal:  Obstet Gynecol       Date:  1991-07       Impact factor: 7.661

5.  Morbid obesity and endometrial cancer: surgical, clinical, and pathologic outcomes in surgically managed patients.

Authors:  James C Pavelka; Inbar Ben-Shachar; Jeffrey M Fowler; Nilsa C Ramirez; Larry J Copeland; Lynne A Eaton; Tom P Manolitsas; David E Cohn
Journal:  Gynecol Oncol       Date:  2004-12       Impact factor: 5.482

6.  Obesity in Patients with Endometrial Cancer: May It Affect the Surgical Outcomes of Laparoscopic Approach?

Authors:  Z M Gambacorti-Passerini; C López-De la Manzanara Cano; C Pérez Parra; M C Cespedes Casas; L Sánchez Hipólito; C Martín Francisco; J R Muñoz-Rodríguez
Journal:  Obes Surg       Date:  2019-10       Impact factor: 4.129

Review 7.  Treatment modalities in endometrial cancer.

Authors:  Frederic Amant; Philippe Moerman; Patrick Neven; Dirk Timmerman; Erik Van Limbergen; Ignace Vergote
Journal:  Curr Opin Oncol       Date:  2007-09       Impact factor: 3.645

8.  Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

Authors:  C P Morrow; B N Bundy; R J Kurman; W T Creasman; P Heller; H D Homesley; J E Graham
Journal:  Gynecol Oncol       Date:  1991-01       Impact factor: 5.482

9.  Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma.

Authors:  M Hendrickson; J Ross; P Eifel; A Martinez; R Kempson
Journal:  Am J Surg Pathol       Date:  1982-03       Impact factor: 6.394

10.  Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.

Authors:  Amanda Nickles Fader; Christa Nagel; Allison E Axtell; Kristine M Zanotti; Joseph L Kelley; Kathleen N Moore; Angeles Alvarez Secord; Christine S Walsh; Warner K Huh; Paola A Gehrig; Heidi Gibbons; Peter G Rose; Laura J Havrilesky; Erin Tuller; Richard D Drake; Justin Bottsford-Miller; David M O'Malley
Journal:  Gynecol Oncol       Date:  2009-01-01       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.